Literature DB >> 21865389

MyD88 plays an essential role in inducing B cells capable of differentiating into antibody-secreting cells after vaccination.

Sang-Moo Kang1, Dae-Goon Yoo, Min-Chul Kim, Jae-Min Song, Min-Kyung Park, Eunju O, Fu-Shi Quan, Shizuo Akira, Richard W Compans.   

Abstract

We investigated the roles of MyD88, an innate adaptor signaling molecule, in inducing protective humoral immunity after vaccination with influenza virus-like particles (VLPs). MyD88 knockout C57BL/6 mice (MyD88(-/-) mice) vaccinated with influenza VLPs showed significant defects in inducing IgG2a/c isotype antibodies and in generating splenic recall memory B cell responses and antibody-secreting plasma cells in the bone marrow. The protective efficacy of influenza VLP vaccination was lower in MyD88(-/-) mice than in the wild-type mice. Our findings indicate that MyD88-mediated innate signaling pathways are important for effectively inducing primary and boost immune responses, T helper type 1 isotype-switched antibodies, and gamma interferon (IFN-γ)-secreting T cell responses. In particular, the results in this study demonstrated for the first time that MyD88-mediated immune activation is likely an essential pathway for effective generation of long-lived antibody-secreting plasma cells and highly protective immunity after vaccination with influenza VLPs. This study provides insight into mechanisms by which recombinant viral vaccines induce protective immunity via the MyD88-mediated innate immune signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21865389      PMCID: PMC3194946          DOI: 10.1128/JVI.00080-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Toll-like receptors control activation of adaptive immune responses.

Authors:  M Schnare; G M Barton; A C Holt; K Takeda; S Akira; R Medzhitov
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

Review 2.  Studies of the humoral immune response.

Authors:  G Kelsoe
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 3.  Extrafollicular antibody responses.

Authors:  Ian C M MacLennan; Kai-Michael Toellner; Adam F Cunningham; Karine Serre; Daniel M-Y Sze; Elina Zúñiga; Matthew C Cook; Carola G Vinuesa
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

4.  DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL.

Authors:  Mikhail B Litinskiy; Bernardetta Nardelli; David M Hilbert; Bing He; Andras Schaffer; Paolo Casali; Andrea Cerutti
Journal:  Nat Immunol       Date:  2002-08-05       Impact factor: 25.606

5.  Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system.

Authors:  Shane Crotty; Rachael D Aubert; John Glidewell; Rafi Ahmed
Journal:  J Immunol Methods       Date:  2004-03       Impact factor: 2.303

6.  mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties.

Authors:  Dong-chul Kang; Rahul V Gopalkrishnan; Qingping Wu; Eckhard Jankowsky; Anna Marie Pyle; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

7.  Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA.

Authors:  Sandra S Diebold; Tsuneyasu Kaisho; Hiroaki Hemmi; Shizuo Akira; Caetano Reis e Sousa
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

8.  Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine.

Authors:  Qizhi Yao; Rongxin Zhang; Lizheng Guo; Min Li; Changyi Chen
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

9.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.

Authors:  Mitsutoshi Yoneyama; Mika Kikuchi; Takashi Natsukawa; Noriaki Shinobu; Tadaatsu Imaizumi; Makoto Miyagishi; Kazunari Taira; Shizuo Akira; Takashi Fujita
Journal:  Nat Immunol       Date:  2004-06-20       Impact factor: 25.606

10.  Influenza virus-like particles containing M2 induce broadly cross protective immunity.

Authors:  Jae-Min Song; Bao-Zhong Wang; Kyoung-Mi Park; Nico Van Rooijen; Fu-Shi Quan; Min-Chul Kim; Hyun-Tak Jin; Andrew Pekosz; Richard W Compans; Sang-Moo Kang
Journal:  PLoS One       Date:  2011-01-18       Impact factor: 3.240

View more
  27 in total

Review 1.  Regulation of B-cell responses by Toll-like receptors.

Authors:  Edward P Browne
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

2.  Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.

Authors:  Min-Chul Kim; Jeong Woo Lee; Hyo-Jick Choi; Yu-Na Lee; Hye Suk Hwang; Jongsang Lee; Cheol Kim; Jong Seok Lee; Carlo Montemagno; Mark R Prausnitz; Sang-Moo Kang
Journal:  J Control Release       Date:  2015-05-21       Impact factor: 9.776

3.  Virus-like particle vaccine confers protection against a lethal newcastle disease virus challenge in chickens and allows a strategy of differentiating infected from vaccinated animals.

Authors:  Jae-Keun Park; Dong-Hun Lee; Seong-Su Yuk; Erdene-Ochir Tseren-Ochir; Jung-Hoon Kwon; Jin-Yong Noh; Byoung-Yoon Kim; Soo-Won Choi; Sang-Moo Kang; Joong-Bok Lee; Seung-Yong Park; In-Soo Choi; Chang-Seon Song
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

4.  Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.

Authors:  Michela Brazzoli; Diletta Magini; Alessandra Bonci; Scilla Buccato; Cinzia Giovani; Roland Kratzer; Vanessa Zurli; Simona Mangiavacchi; Daniele Casini; Luis M Brito; Ennio De Gregorio; Peter W Mason; Jeffrey B Ulmer; Andrew J Geall; Sylvie Bertholet
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

5.  Cellular Immune Correlates Preventing Disease Against Respiratory Syncytial Virus by Vaccination with Virus-Like Nanoparticles Carrying Fusion Proteins.

Authors:  Young-Tae Lee; Eun-Ju Ko; Ki-Hye Kim; Hye Suk Hwang; Youri Lee; Young-Man Kwon; Min-Chul Kim; Yu-Na Lee; Yu-Jin Jung; Sang-Moo Kang
Journal:  J Biomed Nanotechnol       Date:  2017-01       Impact factor: 4.099

6.  TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice.

Authors:  Victoria Jeisy-Scott; Jin Hyang Kim; William G Davis; Weiping Cao; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

7.  TLR3- and MyD88-dependent signaling differentially influences the development of West Nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidate.

Authors:  Jingya Xia; Evandro R Winkelmann; Summer R Gorder; Peter W Mason; Gregg N Milligan
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

8.  Nucleotide oligomerization and binding domain 2-dependent dendritic cell activation is necessary for innate immunity and optimal CD8+ T Cell responses to influenza A virus infection.

Authors:  Christopher Lupfer; Paul G Thomas; Thirumala-Devi Kanneganti
Journal:  J Virol       Date:  2014-05-28       Impact factor: 5.103

9.  Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.

Authors:  Min-Chul Kim; Jong-Seok Lee; Young-Man Kwon; Eunju O; Youn-Jeong Lee; Jun-Gu Choi; Bao-Zhong Wang; Richard W Compans; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2013-06-27       Impact factor: 5.970

10.  Asthma increases susceptibility to heterologous but not homologous secondary influenza.

Authors:  Yoichi Furuya; Sean Roberts; Gregory J Hurteau; Alan M Sanfilippo; Rachael Racine; Dennis W Metzger
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.